Imatinib and Vinorelbine: good results in phase I trials

jenrio

Results for I/II reported here:

http://abstract.asco.org/AbstView_114_98065.html

Within "ITT>28," the response rate was 13.6%, CBR 72.7% and median TTP 176 days.   That's pretty impressive!   A small study and not blinded.  Patient selection (whether patients were chemo-naive or on their 3rd 4th line of chemo) would make a big difference.   Imatinib is a highly targetted and highly effective medicine developed for stomach cancer.   Single-agent Imatinib has been tried before on MBC patients with certain mutations, results were bad.    I am not sure why this combo works better, but in a week we will learn more at the actual meeting.   The abstract gives this hint:

"Imatinib facilitates higher intratumoral cytotoxic drug concentrations".    So maybe imatinib can be combined with taxol or other highly effective MBC cytotoxic drugs to deliver better results?

Clinical trial for phase II/III here:  

http://clinicaltrials.gov/ct2/show/NCT00372476?term=imatinib+breast+cancer&rank=6

mkkjd60

I just want to thank you, Jenrio, for keeping us updated on the latest.  Every post like this makes me hopeful that my mom will become truly chronic with her stage iv bc. 

BaseballFan

I see this trial is being conducted in Germany.  Can we participate here in the U.S.A.?